Second line chemotherapy for NSCLC: establishing a gold standard
- 1 December 2002
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 38, 5-12
- https://doi.org/10.1016/s0169-5002(02)00167-8
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2002
- Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non--small cell lung cancer.Seminars in Oncology, 2001
- A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancerLung Cancer, 2000
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- Activity of Docetaxel in Platinum-Treated Non–Small-Cell Lung Cancer: Results of a Phase II Multicenter TrialJournal of Clinical Oncology, 2000
- Single-Agent Paclitaxel in the Treatment of Advanced Non-Small Cell Lung CancerThe Oncologist, 1999
- Gemcitabine as Second-Line Treatment for Advanced Non–Small-Cell Lung Cancer: A Phase II TrialJournal of Clinical Oncology, 1999
- Second-Line Chemotherapy with 96-Hour Infusional Paclitaxel in Refractory Non-Small Cell Lung Cancer: Report of a Phase II TrialCancer Investigation, 1999
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancerCancer, 1995